Hematology (all articles)
Review | Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
28 Feb, 2023 | 14:00h | UTCAntiphospholipid syndrome: advances in diagnosis, pathogenesis, and management – The BMJ
Cohort Study | Risk of second primary malignancies in patients with chronic lymphocytic leukemia
28 Feb, 2023 | 13:27h | UTC
Commentary on Twitter
Our recent population-based study shows that patients with chronic lymphocytic leukemia (CLL) have an increased risk of developing second primary malignancies (SPMs) in the long term. 1/3#CLLsm #OpenAccess #NKRdata #IKNL @BloodCancerJnl @IKNL https://t.co/epgVnnwv2W
— Dr. Avinash Dinmohamed (@ADinmohamed) January 19, 2023
Single-arm study | Two-year outcomes of Valoctocogene Roxaparvovec therapy for Hemophilia A
27 Feb, 2023 | 12:51h | UTCTwo-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In the GENEr8-1 trial, participants with hemophilia A received B-domain–deleted factor VIII gene therapy delivered in an AAV5 vector. A decrease in annualized bleeding rates was maintained for 2 years despite declining factor VIII levels. https://t.co/hYy3pT8ssa#hematology pic.twitter.com/HuJQa0HiTR
— NEJM (@NEJM) February 23, 2023
Sepsis-induced coagulopathy: an update on pathophysiology, biomarkers, and current guidelines
27 Feb, 2023 | 12:36h | UTCSepsis-Induced Coagulopathy: An Update on Pathophysiology, Biomarkers, and Current Guidelines – Life
Related:
Review | How to manage coagulopathies in critically ill patients
M-A | COVID-19 convalescent plasma outpatient therapy may prevent hospitalizations
23 Feb, 2023 | 13:37h | UTC
Single-arm study | Andexanet Alfa seems effective for the reduction of bleeding associated with factor Xa inhibitors
22 Feb, 2023 | 12:29h | UTCFinal Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors – Circulation
Review | How to manage coagulopathies in critically ill patients
21 Feb, 2023 | 11:43h | UTCHow to manage coagulopathies in critically ill patients – Intensive Care Medicine
Commentary on Twitter
Coagulopathies severe/frequent complication in #ICU: how to manage??
? hemorrhagic coagulopathies: non‑malignant & malignant
? thrombotic c.: sepsis‑induced & solid cancer‑associated
? managing hemorrhagic c.
?(preventing &) managing thrombotic c.
?️ https://t.co/CKqzT7dcoH pic.twitter.com/SvpPNf0oGO— Intensive Care Medicine (@yourICM) February 18, 2023
RCT | Testing equivalence of two doses of intravenous iron to treat iron deficiency in pregnancy
14 Feb, 2023 | 10:31h | UTC
RCT | Ide-cel (a CAR-T cell treatment) vs. standard regimens in relapsed and refractory multiple myeloma
13 Feb, 2023 | 12:41h | UTCIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Ide-Cel Beneficial in Relapsed, Refractory Multiple Myeloma – HealthDay
Ide-cel Improves PFS vs SOC in Relapsed/Refractory Multiple Myeloma – OncLive
RCT | Allo-HCT vs. standard consolidation chemotherapy in patients with intermediate-risk AML
13 Feb, 2023 | 12:40h | UTCAllogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary on Twitter
Rand trial suggests pts with intermediate-risk AML & matched donor have a significantly improved disease free-survival with allo-HCT during first complete remission (69% vs. 40%) but similar overall surv w/consol chemo & allo HCT only after relapse. https://t.co/TJR9fqcYc9
— JAMA Oncology (@JAMAOnc) February 9, 2023
Review | Management of adult patients with hematological malignancies in critical care
10 Feb, 2023 | 13:45h | UTCManagement of adult patients with haematological malignancies in critical care – Anaesthesia
M-A | Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia
9 Feb, 2023 | 13:30h | UTC
Cohort Study | Risk of primary hematologic cancers following incident non-metastatic breast cancer
8 Feb, 2023 | 12:11h | UTC
M-A | Heparin full-dose anticoagulation is beneficial for non-critically ill COVID-19 patients
7 Feb, 2023 | 14:06h | UTCRelated:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Podcast | Hemochromatosis pearls
7 Feb, 2023 | 13:53h | UTC#380 Hemochromatosis with Elliot Tapper – The Curbsiders
Case-control study | Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985-2010
6 Feb, 2023 | 13:20h | UTCInvited Commentary: Heart Failure in Patients With Cancer Treated With Anthracyclines—Revisiting the Foundation of Cardio-Oncology- JAMA Network Open
Commentary on Twitter
Anthracycline is linked to double the rate of heart failure in patients with cancer vs matched controls, 7.4% at 15 years. https://t.co/SxlJkJ7oLR
— JAMA Network Open (@JAMANetworkOpen) February 3, 2023
SR | Efficacy of CAR-T cell therapy vs. auto-HSCT in relapsed or refractory diffuse large B-cell lymphoma
6 Feb, 2023 | 13:06h | UTC
Epidemiology, clinical presentation, and outcomes of 620 patients with eosinophilia in the intensive care unit
3 Feb, 2023 | 14:15h | UTC
Commentary on Twitter
? Eosinophilia? Not uncommon in #ICU! Depending on timing, 2 subsets of pts, corresponding to different underlying diseases/different patterns of eosinophil-induced organ damage & requiring different etiological workups/management can be distinguished.
?️ https://t.co/nr1EHHnYGa pic.twitter.com/VBWpJKUGrv— Intensive Care Medicine (@yourICM) February 2, 2023
Transfusion thresholds for acute coronary syndromes — insights from the TRICS‐III trial and meta‐analysis
3 Feb, 2023 | 13:58h | UTC
Preliminary study suggests chemotherapy delivery in the afternoon may improve outcomes in patients with DLBC lymphoma
1 Feb, 2023 | 13:27h | UTCCommentaries:
Chemotherapy schedule affects treatment outcomes in female DLBCL patients – News Medical
RCT | Effects of once-weekly prophylaxis with Efanesoctocog Alfa in patients with severe Hemophilia A
30 Jan, 2023 | 01:14h | UTCEfanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Once-Weekly Efanesoctocog Alfa Beneficial in Severe Hemophilia A – HealthDay
Commentary on Twitter with a video summary
Efanesoctocog alfa is a new class of factor VIII replacement for hemophilia A that has a longer half-life than other factor VIII products, thus allowing once-weekly dosing. New research findings are summarized in a short video. https://t.co/YuXzifUh8m pic.twitter.com/POCAAfeEni
— NEJM (@NEJM) January 27, 2023
Practice Guidance | Anticoagulation in adult patients supported with extracorporeal membrane oxygenation
30 Jan, 2023 | 00:56h | UTC
RCT | IV ferric carboxymaltose vs. oral ferrous fumarate in anemic children with inflammatory bowel disease
30 Jan, 2023 | 00:18h | UTC
Cohort Study | Risk of malignant neoplasms of the gastrointestinal tract after blood or marrow transplant
30 Jan, 2023 | 00:23h | UTCMalignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation – The ASCO Post
Commentary on Twitter
Exposure to cytarabine, etoposide and anthracyclines & chronic graft vs. host disease increase risk of colorectal, liver & esophageal cancer after BMT, providing evidence for appropriate evaluation & management in high-risk populations. https://t.co/UENFM1UWRw
— JAMA Oncology (@JAMAOnc) January 23, 2023
Cohort Study | Incidence and impact of anticoagulation-associated abnormal menstrual bleeding after VTE
27 Jan, 2023 | 12:04h | UTCInvited Commentary: The burden of heavy menstrual bleeding – Blood
Commentary on Twitter
Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism https://t.co/IEftFzyvRl pic.twitter.com/m09sP14inN
— Blood Journal (@BloodJournal) October 26, 2022